Share on StockTwits

Thoratec (NASDAQ:THOR) has received a consensus rating of “Buy” from the fourteen analysts that are covering the stock, AnalystRatings.NET reports. Three investment analysts have rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $42.00.

A number of research firms have recently commented on THOR. Analysts at Raymond James cut their price target on shares of Thoratec from $44.00 to $41.00 in a research note on Monday, July 14th. Separately, analysts at TheStreet upgraded shares of Thoratec from a “hold” rating to a “buy” rating in a research note on Tuesday, July 8th. Finally, analysts at JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Thoratec in a research note on Thursday, July 3rd. They now have a $35.00 price target on the stock, up previously from $31.00.

Thoratec (NASDAQ:THOR) opened at 32.68 on Friday. Thoratec has a 52-week low of $30.01 and a 52-week high of $43.58. The stock has a 50-day moving average of $33.89 and a 200-day moving average of $34.48. The company has a market cap of $1.856 billion and a P/E ratio of 25.98.

Thoratec (NASDAQ:THOR) last released its earnings data on Tuesday, May 6th. The company reported $0.41 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.39 by $0.02. The company had revenue of $125.70 million for the quarter, compared to the consensus estimate of $122.56 million. During the same quarter last year, the company posted $0.41 earnings per share. Thoratec’s revenue was up 6.8% compared to the same quarter last year. On average, analysts predict that Thoratec will post $1.76 earnings per share for the current fiscal year.

Thoratec Corporation is engaged in mechanical circulatory support with a product portfolio to treat the range of clinical needs for advanced heart failure (NASDAQ:THOR) patients.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.